Approval · Notice of Compliance 1218 · 2000
AVAPRO: Notice of Compliance 1218
Issued September 18, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1218
- Date
- September 18, 2000
- Company
- Sanofi-Synthelabo Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Angiotensin ii at1 receptor blocker
Products in this notice
Medicinal ingredients
- IRBESARTAN 75 MG per TAB
- IRBESARTAN 150 MG per TAB
- IRBESARTAN 300 MG per TAB